C. R. Bard: Business overview
C. R. Bard (BCR) generates revenues from manufacturing, selling, and marketing medical devices in the following business segments:
- Surgical Specialties
The Vascular segment consists of a portfolio of minimally invasive devices for the treatment of heart arrhythmias, ESRD (end stage renal disease) and PVD (peripheral vascular disease) through endovascular devices and grafts.
The Vascular segment accounts for around 28% of the company’s total revenues. Some of the key products in this segment include peripheral angioplasty catheters, peripheral vascular stents, vena cava filters, and drug-coated balloons. Boston Scientific (BSX), St. Jude Medical (STJ), and Abbott (ABT) are some of the major competitors in this space.
C. R. Bard’s Urology segment consists of basic drainage devices, continence devices, urological specialty products, catheter stabilization devices, and targeted temperature management products. The segment accounted for 25% of the company’s total revenues in 2015. The Foley catheter is the company’s key product in the Urology segment. Medtronic and Boston Scientific are C. R. Bard’s major competitors in this segment.
The oncology device segment consists of products used for the treatment and management of cancers and related conditions. These products include specialty vascular access ports and catheters used primarily for chemotherapy, ultrasound devices, dialysis access catheters, and PICCs (peripherally inserted central catheters) used for central venous access. The segment’s sales accounted for 27% of C. R. Bard’s total revenues in 2015. Some major competitors in this space include Boston Scientific and Becton, Dickinson and Company.
C. R. Bard’s Surgical Specialties segment accounts for 17% of the company’s total revenues. The segment consists of products and devices used for hernias and soft tissue repairs. C. R. Bard is the leader in the groin hernia repair market. Its product line includes implanted grafts, fixation devices, hemostats, and surgical sealants. Major competitors in this space include Medtronic and Johnson & Johnson. One of the major ETFs with exposure to C. R. Bard is the Health Care Select Sector SPDR ETF (XLV), which has 0.65% of its total holdings in BCR.